AIM ImmunoTech (AIM) stock rocketed higher on Thursday after the immuno-pharma company announced year-end interim clinical progress from its Phase 2 study of Ampligen combined with AstraZeneca’s (AZN) Imfinzi. Ampligen is being evaluated as a treatment for metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX standard of care.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
AIM ImmunoTech noted that the survival period of patients in the study increased to a median of 19.7 months. That’s a huge increase over the median standard of care survival period, which is only 8.6 months. The company also noted that patients reported improved quality of life.
Thomas K. Equels, CEO of AIM ImmunoTech, said, “This data sharply focuses our aim on late-stage pancreatic cancers, which killed more than 100,000 people in the American and European Union markets and more than 450,000 people worldwide as recently as 2022. I do not believe there is any other therapeutic in this stage of the pipeline that is producing these types of survival results combined with improvement in quality of life.”
AIM ImmunoTech Stock Movement Today
AIM ImmunoTech stock was up 45.02% in pre-market trading on Thursday, following an 8.26% fall yesterday. The shares have also decreased 6.47% year-to-date and 93.12% over the past 12 months.
With today’s news came heavy trading of AIM stock, as more than 20 million shares changed hands, compared to a three-month daily average trading volume of about 150,000 units.
Is AIM ImmunoTech Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for AIM ImmunoTech is Moderate Buy, based on a single Buy rating over the past three months. With that comes an average AIM stock price target of $22, representing a potential 1,985.31% upside for the shares.
